Survival from Diagnosis Early Mortality and Recorded Systemic Therapy Lines in a Turkish Small Cell Lung Cancer Analytic Cohort

Background/Objectives: We described survival from diagnosis, early mortality, and recorded systemic therapy lines and explored the association between baseline brain metastases and mortality in a Turkish small cell lung cancer (SCLC) cohort. Methods: This retrospective single-center study included 131 eligible adults. Observed diagnoses ranged from 12 August 2009 to 23 May 2023. All included patients had died by follow-up ascertainment. Additional brain-metastasis analyses and calendar-period comparisons were exploratory and post hoc. Treatment calendar details, immunotherapy exposure, and cranial radiotherapy details were unavailable. Results: Median overall survival (OS) was 10.41 months (95% confidence interval [CI], 8.74–13.04); 30- and 90-day mortality were 5.3% and 12.2%. First-line platinum–etoposide was recorded in 99 patients (75.6%). Of 22 limited-stage patients, 21 received concurrent thoracic chemoradiotherapy with curative intent; one patient could not start anticancer therapy after pneumonia and rapid clinical deterioration. Within extensive-stage disease, the unadjusted brain-metastasis hazard ratio (HR) was 1.67 (95% CI, 0.98–2.86; p = 0.061), the log-rank p value was 0.059, and the adjusted HR was 1.98 (95% CI, 1.07–3.66; p = 0.029). A 5000-replicate bootstrap gave a percentile 95% CI of 1.10–4.87 and a bias-corrected and accelerated (BCa) 95% CI of 0.84–3.79. The original full-cohort brain-metastasis p value was 0.033 and became 0.099 after Bonferroni or Holm adjustment across three baseline findings. Conclusions: The analyses suggested a possible association between baseline brain metastases and higher mortality, but the original full-cohort association did not meet the significance threshold after Holm correction. Sparse exposure and unmeasured confounding make this finding hypothesis-generating. Clinic-based referral selection may limit generalizability.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229083
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Survival from Diagnosis Early Mortality and Recorded Systemic Therapy Lines in a Turkish Small Cell Lung Cancer Analytic Cohort

Oğuzhan Kesen, Ali Çelik
Journal of Clinical Medicine
Lung Cancer Research Studies
article

Survival from Diagnosis Early Mortality and Recorded Systemic Therapy Lines in a Turkish Small Cell Lung Cancer Analytic Cohort

Oğuzhan Kesen, Ali Çelik
article en

Abstract

Background/Objectives: We described survival from diagnosis, early mortality, and recorded systemic therapy lines and explored the association between baseline brain metastases and mortality in a Turkish small cell lung cancer (SCLC) cohort. Methods: This retrospective single-center study included 131 eligible adults. Observed diagnoses ranged from 12 August 2009 to 23 May 2023. All included patients had died by follow-up ascertainment. Additional brain-metastasis analyses and calendar-period comparisons were exploratory and post hoc. Treatment calendar details, immunotherapy exposure, and cranial radiotherapy details were unavailable. Results: Median overall survival (OS) was 10.41 months (95% confidence interval [CI], 8.74–13.04); 30- and 90-day mortality were 5.3% and 12.2%. First-line platinum–etoposide was recorded in 99 patients (75.6%). Of 22 limited-stage patients, 21 received concurrent thoracic chemoradiotherapy with curative intent; one patient could not start anticancer therapy after pneumonia and rapid clinical deterioration. Within extensive-stage disease, the unadjusted brain-metastasis hazard ratio (HR) was 1.67 (95% CI, 0.98–2.86; p = 0.061), the log-rank p value was 0.059, and the adjusted HR was 1.98 (95% CI, 1.07–3.66; p = 0.029). A 5000-replicate bootstrap gave a percentile 95% CI of 1.10–4.87 and a bias-corrected and accelerated (BCa) 95% CI of 0.84–3.79. The original full-cohort brain-metastasis p value was 0.033 and became 0.099 after Bonferroni or Holm adjustment across three baseline findings. Conclusions: The analyses suggested a possible association between baseline brain metastases and higher mortality, but the original full-cohort association did not meet the significance threshold after Holm correction. Sparse exposure and unmeasured confounding make this finding hypothesis-generating. Clinic-based referral selection may limit generalizability.

Journal of Clinical MedicineVol. 15(22)
Recep Tayyip Erdoğan University (TR)
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon